Omnicare — Q3 2012 Earnings Presentation
17 slides from Omnicare's earnings presentation, Oct 31, 2012
Slide 1: Third Quarter 2012 Financial Results Supplemental Slides
Slide 2: Forward-Looking Statements
Forward-Look Statements Cc i of the Pri lies Litigation Reform Act of 1995. These forwarcHooking ‘statements. indude, but all statements ‘or current expectations presentation. k id unknown risks, uncertainties, conti differ materially The most significant of Company's Form 10-K, Form 10-Q and Form 8
Slide 3: Table of Contents
Table of Contents Third Quarter 2012 Highlights Operating Metrics — Script Data Operating Metrics — Long-Term Care Bed Data... Gross Profit & Adjusted Operating Income. Adjusted Net Income & Cash-based EPS. . Adjusted Operating Income by Segment ........00::c::cscsesccs sneer eaeeed 9 Cash Flows Cas
Slide 4: Third Quarter 2012 Highlights
Third Quarter 2012 Highlights Gross profit 7.3% higher year-over-year to $371.3M on 232 bps margin increase Adjusted EBITDA") increased 9.5% year-over-year to $172.2M Adjusted Cash-Based EPS)®) of $0.86; 16.2% increase over $0.74 in 3Q11 Long-Term Care Group third-quarter performance: — Net sales 8.
Slide 5: Operating Metrics: Script Data
Operating Metrics Script Data Sequential Prior Year Increase / (In thousands, except %s) 3Q2012 2Q2012 (Decrease) _3Q2011 (Decrease! Long-Term Care Group Scripts: Generic scripts dispensed 20,586 20,528 0.3% 20,786 (1.0%) Branded scripts dispensed 4,083 4,372 (6.6%) 4,123 (1.0%) Over-the-counter se
Slide 6: Operating Metrics: Long-Term Care Bed Data
Operating Metrics Long-Term Care Bed Data Sequential Prior Year Increase / Increase / (In thousands) 3Q2012 2Q2012 (Decrease) 3Q2011 (Decrease) Beds served: ———————— Beginning of period - LTC Beds 977 986 (9) 1,003 (26) Net change in beds served 3 9) 12 (2) End of period - LTC Beds 980 977 3 1,008 (
Slide 7: Gross Profit & Adjusted Operating Income
Gross Profit & Adjusted Operating Income (1)(2) Sequential Prior Year / In ! In millions, except per share data and %s 3.2012 202012 (Decrease) _3Q2011 (Decrease) Net sales $1,501 (2.3%) 1544. (2.8%) Cost of sales 4,130.1 1,168.7 (3.3%) 1,198.3 (6.7%) Gross profit $371.3 367.3 1.1% $ 346.1 7.3% 24.7
Slide 8: Adjusted Net Income & Cash-based EPS
Adjusted Net Income & Cash-based EPS")() Sequential Prior Year Increase / n millions, xcept per share data and %s 32012 22012 (Dectease) _302011 \justed operating i $ 1437 § 1414 1.6% $ 130. pcustes interest expense, net of ica income (249) (25.5) (2.4%) (23.7) Acisie fed income before income tax 11
Slide 9: Adjusted Operating Income by Segment
Adjusted Operating Income by Segment “) Sequential Prior Year Increase / Increase / 30.2012 2.2012 _(Decrease! 3Q 2011 Decrease) In millions, except %s Long-Term Care Group Net sales $ 1,165.7 $ 1,202.8 (3.1%) $ 1,266.6 (8.0%) ‘Adjusted operating income from continuing perations® operations: 154.4 1
Slide 10: Cash Flows
Cash Flows (1) —Sequential__ Prlor Year. Increase / Increase / In deisel except %S 3Q2012 2Q 2012 (Decrease) _3Q2011 (Decrease) $ 614 228.3% 27.9 (120.1%) tee "yom discontinued operat - : - 9.9 (100.0%) usta nts to reconcile net income to net cash flows from operating Depreciation expense 138 012.4
Slide 11: Cash Deployment
Cash Deployment Increase / Increase / In ions except %s 3Q.2012 22012 (Decrease) _302011 (oscromss| Net c: from operating activities of aeurtrg operations (reported) $196.3 $ 120.2 63.2% $ 167.41 17.5% Capital expenditures 25.0 26.2 (4.6%) 209 19.9% Acquisitions 33.8 : : 823 (58.9%) Net debt and lon
Slide 12: Capital Structure
Capital Structure Major Debt Maturity Schedule” (in $ millions) $1,500 WAs of 9/30/10 @As of 9/30/12 2010 2015 2020 2025 2030 2035
Slide 13: 2012 Guidance
2012 Guidance Original Previous Current Guidance () Guidance “) Guidance “) - Revenue $6.1B to $6.2B $6.1B to $6.2B $6.1B to $6.2B » Adjusted cash earnings per diluted share® $3.10 to $3.20 $3.22 to $3.28 $3.30 to $3.36 . Sean $400M to $500M $425M to $525M — $500M to $550M
Slide 14: Appendix
Slide 15: Working Capital Management
Working Capital Management Five Quarter Trend() 40 Ba 30 =a 3 2 69 325 26.3 20 63 * —a—eKo—___. ° $5.2 so oO 51 3ai1 oat 1ai2 2012 3a12
Slide 16: Selected Branded Drug Patent Expirations
Selected Branded Drug Patent Expirations():(2) 302072 FY'3073 Actos Aciphex Actos Plus Comtan Asacol Detrol IR Diovan IR Cerezyme Diovan/HCTZ Evoxac Cymbalta Dovenex CM Gabitril Fosamax D Fazaclo Maxalt Fosrenol ‘Singulair ‘Mucinex (re-launch) Lescol XR Symbyax Revatio Lidoderm Trileptal Susp. (re-l
Slide 17: Slide 17